Basal | Minimum | Maximum | Distribution | Ref | |
Utilities | |||||
Active disease | 0.41 | 0.33 | 0.5 | – | 21 |
Response | 0.76 | 0.61 | 0.91 | – | 21 |
Remission | 0.87 | 0.70 | 1 | – | 21 |
Surgery | 0.68 | – | – | BETA (α=83.77; β=39.42) | 20 35 |
Surgery complication | 0.49 | – | – | BETA (α=56.91; β=59.23) | 20 35 |
Surgery remission | 0.68 | – | – | BETA (α=83.77; β=39.42) | 20 35 |
Disutilities for adverse events | |||||
Mean (SD) | Ref | ||||
Infliximab | −0.1 | 18 | |||
RR golimumab vs infliximab | 1.23 (1.54) | 18 | |||
RR adalimumab vs infliximab | 1.35 (1.33) | 18 | |||
RR vedolizumab vs infliximab | 1.46 (1.61) | 18 | |||
RR tofacitinib vs infliximab | 0.96 (1.57) | 18 |
Ref, Reference; RR, Relative risk; SD, Standard deviation